SCHEMBL22808233

SCHEMBL22808233

CCCC(C)c1ccc(Cl)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.48
MAPK1 P28482 2/20 0.48
NPC1 O15118 3/20 0.39
GLA P06280 1/20 0.39
TSHR P16473 2/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
RAB9A P51151 3/20 0.36
ALDH1A1 P00352 2/20 0.36
FFAR2 O15552 1/20 0.36
KMO O15229 1/20 0.36
APLNR P35414 1/20 0.35
ADRA2A P08913 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
MAPT P10636 1/20 0.35
BRD4 O60885 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19232028 0.86 MAPK1 (0.41) L3MBTL1MAPK1NPC1GLATSHR
SCHEMBL13677282 0.85 MAPT (0.42) L3MBTL1MAPK1TSHRESR1ESR2
SCHEMBL19464637 0.85 MAPT (0.42) L3MBTL1MAPK1TSHRESR1ESR2
SCHEMBL13104799 0.85 MAPT (0.42) L3MBTL1MAPK1TSHRESR1ESR2
SCHEMBL13678865 0.83 MAPK1 (0.45) L3MBTL1MAPK1NPC1GLATSHR
SCHEMBL20376066 0.80 MAPK1 (0.43) L3MBTL1MAPK1NPC1GLATSHR
SCHEMBL24501229 0.79 ESR1 (0.42) L3MBTL1MAPK1NPC1ESR1ESR2
SCHEMBL3532948 0.79 ESR1 (0.39) L3MBTL1MAPK1NPC1ESR1ESR2
SCHEMBL17828000 0.79 CCR1 (0.40) ESR1ESR2RAB9AALDH1A1KMO
SCHEMBL18885418 0.78 APLNR (0.44) MAPK1ESR1ESR2ALDH1A1KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10869934-B2 Antiproliferative compounds and conjugates made therefrom BRISTOL-MYERS SQUIBB COMPANY (US) 2020-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10869934-B2 Antiproliferative compounds and conjugates made therefrom MKI67, HDGF, PCLAF L3MBTL1 1994/4885MAPK1 817/4885NPC1 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.